Keeping up with our coverage for our readers regarding the Covid-19 pandemic, some new research and information about a potential Vaccine has made headlines today.
In an article posted on Bloomberg earlier today, they speculated that a vaccine could be available as early as this year. Citing The Coalition for Epidemic Preparedness Innovations previous target of 12 to 18 months, more light was shed on the subject when it was realized that this initial assessment did not include some measures that are now being taken. We are seeing more rapid enrollment for human trials related to potential vaccines, and more large companies are jumping in to help aid in the vaccine pursuit. Bloomberg points out that Sanofi, Johnson & Johnson and Moderna Inc. are among dozens of different companies. Johnson & Johnson you’ve undoubtedly heard of, but Sanofi is a world leader in pharmaceuticals, and Moderna is a Massachusetts-based biotechnology company that is focused on drug discovery and drug development.
Something positive to note, is that “A University of Oxford team led by Sarah Gilbert, a professor of vaccinology, has begun trials of a potential vaccine and aims to get efficacy results as soon as September. Manufacturing is already underway.”
While all of this seems like good news, some experts have said to take caution with this information given that most vaccines actually take years to go through trials and see effectiveness against viruses. According to the article written in Bloomberg today, the covid-19 methods and trials that are moving through testing the fastest are being made with technology that really has never proven to be useful with humans.
Nevertheless, the CEPI remains hopeful to see several vaccines enter a second phase of testing by the summer, meaning the first vaccines could be available this year. It’s important to note that in the past there have been less than fortunate results when rushing vaccine production. The head of CEPI acknowledged this as well when saying “We take it with the utmost seriousness. We cannot cut corners. It’s absolutely critical that we ensure safety and efficacy.”
Another concern with the potential vaccines is where they are developed. The head of Sanofi raised concerns about Europe’s ability to produce enough of the Covid-19 Vaccine, and suggested that the United States may be the ones to vaccinate first. Norway’s prime minister, Erna Solberg, in a call with CEPI stressed, ““We should really have a global perspective and make sure we don’t end up limiting the access because it’s produced in certain countries”.
Be sure to check back to the ABN Blog often for up to date information and reports about Covid-19.